I. Current antiviral therapies

II. Novel indirect-acting antivirals

III. Viral hijacking of cell functions

IV. MICB 406 Symposium

Selected viruses:
- **Flaviviridae**
- **Orthomyxoviridae**
- **Retroviridae**

I. Developing desperately needed new “Direct Acting Antivirals” (DAAs) for emerging and re-emerging human viruses

II. Shifting the current paradigm on global antiviral strategies: from DAAs to “Indirect-Acting Antivirals” (IAAs)

III. What’s next? Discovering novel master regulators of viral infection - The case of cellular and viral microRNAs

(Mid-term break: Feb 18-22)

Jan 03 Start

2 x HW

**Title:** Developing a new multi-drug regimen for the treatment of hepC/HIV co-infection - a deadly human syndrome

**Written Proposal** (CIHR Format) Mandatory (30%)

**Title:** Presenting the "biggest" Nobel-worthy discovery in the field of Molecular Virology: [Novel antiviral treatment?]

**Written Proposal** (CIHR Format) Option 1 (30%)

**Title:** Presenting the "biggest" Nobel-worthy discovery in the field of Molecular Virology: [Novel viral-associated disease?]

**Written Proposal** (CIHR Format) Option 2 (30%)

**Title:** Presenting the "biggest" Nobel-worthy discovery in the field of Molecular Virology: [Novel master regulator of human viral infection?]

**Written Proposal** (CIHR Format) Option 3 (30%)

Feb 14 HW-1

March 7 Abstract Deadline

March 14 Start mini Symposium

April 4 HW-2

10th MICB 406 Science Symposium:
Breaking Down the Scientific Barriers: The Field of “Nobel Dreams” in Molecular Virology
March 14 - April 2, 2013